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Randomized Controlled Trial of Adalimumab in Patients
With Nonpsoriatic Peripheral Spondyloarthritis
Philip Mease,1 Joachim Sieper,2 Filip Van den Bosch,3 Proton Rahman,4
P. Mahinda Karunaratne,5 and Aileen L. Pangan5
Objective. To evaluate the efficacy and safety of
adalimumab in patients with active nonpsoriatic peri-
pheral spondyloarthritis (SpA).
Methods. ABILITY-2 is an ongoing phase III,
multicenter study of adalimumab treatment. Eligible
patients age >18 years fulfilled the Assessment of
SpondyloArthritis international Society (ASAS) classi-
fication criteria for peripheral SpA, did not have a prior
diagnosis of psoriasis, psoriatic arthritis (PsA), or
ankylosing spondylitis (AS), and had an inadequate
response or intolerance to nonsteroidal antiinflamma-
tory drugs (NSAIDs). Patients were randomized 1:1 to
receive adalimumab 40 mg every other week or matching
placebo for 12 weeks, followed by a 144-week open-label
period. The primary end point was the proportion of pa-
tients achieving 40% improvement in disease activity
according to the Peripheral SpA Response Criteria
(PSpARC40) at week 12. This was defined as >40% im-
provement from baseline (>20-mm absolute improve-
ment on a visual analog scale) in patient’s global
assessments of disease activity and pain, and >40%
improvement in at least one of the following features:
swollen joint and tender joint counts, total enthesitis
count, or dactylitis count. Adverse events were recorded
throughout the study.
Results. In total, 165 patients were randomized to
a treatment group, of whom 81 were randomized to
receive placebo and 84 to receive adalimumab. Baseline
demographics and disease characteristics were gener-
ally similar between the 2 groups. At week 12, a greater
proportion of patients receiving adalimumab achieved a
PSpARC40 response compared to patients receiving
placebo (39% versus 20%; P  0.006). Overall, improve-
ment in other outcomes was greater in the adalimumab
group compared to the placebo group. The rates of
adverse events were similar in both treatment groups.
Conclusion. Treatment with adalimumab amelio-
rated the signs and symptoms of disease and improved
physical function in patients with active nonpsoriatic
peripheral SpA who exhibited an inadequate response
or intolerance to NSAIDs, with a safety profile consis-
tent with that observed in patients with AS, PsA, or
other immune-mediated diseases.
The spondyloarthritides (SpA) refer traditionally
to a group of interrelated diseases, which includes
ankylosing spondylitis (AS), psoriatic arthritis (PsA),
reactive arthritis (ReA), inflammatory bowel disease
(IBD)–related arthritis, and undifferentiated SpA
(uSpA). The Assessment of SpondyloArthritis interna-
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tional Society (ASAS) developed and validated updated
classification criteria for SpA on the basis of the pre-
dominant clinical manifestation found in these various
SpA disease subsets, classified as either axial SpA (1) or
peripheral SpA (2).
The ASAS classification criteria for peripheral
SpA (2) were meant to be applied to patients with an
established diagnosis of SpA, peripheral arthritis (usu-
ally asymmetric or predominantly involving the lower
limbs), enthesitis, and/or dactylitis. These criteria en-
compass patients who may have been diagnosed in the
past as having PsA, IBD-related arthritis, ReA, or uSpA
with predominantly peripheral manifestations. Other
than those with PsA, such patients with peripheral SpA
have not been well characterized or included in clinical
trials of new therapies. There is only limited information
on the epidemiology of nonpsoriatic peripheral SpA,
with some data provided in studies of patients with
IBD-related arthritis (3–5) or those with ReA (5,6).
However, the majority of patients with peripheral SpA
present with features typical of SpA, but their disease
overall does not fit in any of these categories. These
patients have been labeled as having uSpA and will
probably benefit most from the new classification crite-
ria for peripheral SpA. For example, the most cited
study about a possible effect of sulfasalazine in patients
with SpA included only patients with AS, PsA, or ReA
(7). Epidemiologic data on this subset are also quite
limited (5,8,9). With the availability of the ASAS peri-
pheral SpA criteria, there is now an opportunity to
classify nonpsoriatic peripheral SpA patients for study
inclusion in a therapeutic clinical trial.
Anti–tumor necrosis factor (anti-TNF) therapy,
including adalimumab, has been proven effective for the
treatment of PsA (10–13). Patients with nonpsoriatic
peripheral SpA may also benefit from anti-TNF therapy.
The efficacy of adalimumab in nonpsoriatic, non-AS
peripheral SpA was demonstrated in a small study from
The Netherlands (14); however, the disease in those
patients was classified using the older European Spon-
dylarthropathy Study Group criteria (15).
ABILITY-2 is the first multicenter, global, ran-
domized controlled trial to be conducted in patients with
nonpsoriatic peripheral SpA. This study evaluated the
efficacy and safety of adalimumab in patients with active
nonpsoriatic peripheral SpA who fulfilled the ASAS
peripheral SpA criteria and who had an inadequate
response to at least 2 nonsteroidal antiinflammatory
drugs (NSAIDs) or were intolerant to, or had a contra-
indication for, NSAIDs.
PATIENTS AND METHODS
Patients. Eligible patients were 18 years of age and
fulfilled the ASAS criteria for peripheral SpA (2), with onset of
peripheral SpA symptoms at least 3 months prior to the study.
Patients with a history of psoriasis or PsA or with a diagnosis
of AS defined by the modified New York criteria (16) were
excluded. Eligible patients must have active disease, defined
as any of the following features: 1) 2 tender joints among a
total of 78 joints assessed, and 2 swollen joints among a
total of 76 joints assessed, 2) 2 digits with dactylitis and 1
joint with active inflammatory arthritis (swollen and tender)
not associated with dactylitis, or 3)2 sites of enthesitis (those
judged by a physician as being severe) among a total of 29
sites assessed, with each site being distinct and not anatomi-
cally related to the same region and no bilateral involve-
ment in the same site, or 4) 2 sites of enthesitis and 1 joint
with active inflammatory arthritis (swollen and tender) not
associated with enthesitis. In addition, patients were required
to have a score of at least 40 mm on a 0–100-mm visual ana-
log scale (VAS) for patient’s global assessment of disease
activity and patient’s global assessment of pain. Moreover, they
must have had an inadequate response to at least 2 NSAIDs
or have been intolerant to, or had a contraindication for,
NSAIDs. Patients with a score of20 mm on the VAS for total
back pain (scale 0–100 mm) were excluded from the study.
Patients with previous exposure to biologic therapy were also
excluded.
Study design and treatment. The ABILITY-2 study,
initiated in March 2010, is an ongoing phase III, randomized,
placebo-controlled, double-blind trial being conducted at 28
centers in Australia, Canada, Europe, and the US. The study
has been performed in accordance with the International
Conference on Harmonisation Guidelines for Good Clinical
Practice and the Declaration of Helsinki. Approval of an
institutional ethics review board and voluntary written in-
formed consent were obtained prior to the initiation of study
procedures.
Eligible patients were centrally randomized using an
interactive voice or web-based response system. Patients were
randomized 1:1 to receive adalimumab 40 mg every other week
subcutaneously or matching placebo for 12 weeks during the
double-blind period. Efficacy and safety were assessed at
weeks 2, 4, 8, and 12. The double-blind period was followed by
an ongoing 144-week open-label period during which patients
received adalimumab 40 mg every other week.
Patients could enter the study while continuing to
receive concomitant treatment with disease-modifying anti-
rheumatic drugs (DMARDs) (methotrexate25 mg per week,
sulfasalazine 3 gm per day, and/or hydroxychloroquine 400
mg per day or azathioprine 150 mg per day) and/or NSAIDs,
if the doses met prespecified stability requirements prior to
randomization and remained stable during the first 12 weeks of
the trial, except when changes were medically required due to
an adverse event (AE).
Efficacy assessments. Primary efficacy end point. Given
the paucity of clinical trials conducted to date in patients with
nonpsoriatic peripheral SpA, no efficacy end point that repre-
sents a measure of improvement in arthritis, enthesitis, and/or
dactylitis has been specifically developed for and validated in
this population. Therefore, a novel composite efficacy outcome
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measure was designed as the primary end point for this study:
the proportion of patients who achieved the Peripheral SpA
Response Criteria (PSpARC40) at week 12. The PSpARC40
was defined as 40% improvement (20-mm absolute im-
provement) from baseline in the VAS scores for patient’s
global assessment of disease activity and patient’s global
assessment of pain, and 40% improvement from baseline in
at least one of the following features: 1) swollen joint count
(SJC) (total of 76 joints assessed) and tender joint count (TJC)
(total of 78 joints assessed), 2) total enthesitis count, or
3) dactylitis count. The total enthesitis count represents the
sum of all unique, individual sites exhibiting enthesitis, com-
prising the anatomic locations included in the Leeds Enthesitis
Index (17), the Spondyloarthritis Research Consortium of
Canada (SPARCC) Enthesitis Index (18), and the Maastricht
Ankylosing Spondylitis Enthesitis Score (MASES) (19).
Secondary efficacy end points. Secondary efficacy vari-
ables analyzed at week 12 included physician’s global assess-
ment of disease activity (0–100-mm VAS), the Bath Ankylos-
ing Spondylitis Disease Activity Index (BASDAI; scale 0–10)
(20), the Health Assessment Questionnaire modified for the
Spondyloarthropathies (HAQ-S) (21), and the Short-Form 36
version 2 (SF-36v2) Health Survey physical component sum-
mary (PCS) score (22). Other variables analyzed at various
time points included the enthesitis assessment, consisting of
the Leeds Enthesitis Index (scale 0–6) (17), SPARCC Enthesi-
tis Index (scale 0–16) (18), and MASES (scale 0–13) (19), the
dactylitis count, the TJC and SJC, and the Ankylosing Spon-
dylitis Disease Activity Score (ASDAS) (23).
In addition to the PSpARC40, different cutoff values
defining levels of improvement, including proportions of pa-
tients achieving 20% (PSpARC20), 50% (PSpARC50), and
70% (PSpARC70) levels of improvement, were also evaluated.
The PSpARC20, PSpARC50, and PSpARC70 were defined as
20%, 50%, and 70% improvement from baseline (10-
mm, 20-mm, or 30-mm absolute improvement), respec-
tively, in the VAS scores for patient’s global assessment of
disease activity and patient’s global assessment of pain, and
20%,50%, and70% improvement from baseline, respec-
tively, in at least one of the following features: the TJC and
SJC, total enthesitis count, or dactylitis count.
Disease remission was evaluated using two composite
measures, the ASDAS and the PSpARC. Inactive disease
based on the ASDAS was defined as an ASDAS score of 1.3
(24). Disease remission based on the PSpARC criteria was
defined as an SJC of 1 and at least 4 of the 5 following
parameters: patient’s global assessment of disease activity VAS
score 20 mm, patient’s global assessment of pain VAS score
20 mm, TJC1, total enthesitis count1, or dactylitis count
1.
Safety assessments. Safety was assessed by evaluating
the frequency of AEs that began or worsened after the first
dose of study medication through 70 days after the last dose.
Statistical analysis. The intent-to-treat population an-
alyzed for efficacy and safety included all randomized patients
who received at least one dose of study medication. A sample
size of 154 patients (77 for the placebo group and 77 for the
adalimumab group) was calculated to provide90% statistical
power to detect a 25% difference in PSpARC40 response rates
between the treatment groups, based on a Pearson’s 2-sided
chi-square test with a level of significance of   0.05.
For categorical variables, patients with missing data at
week 12 were considered to be nonresponders, as determined
using nonresponder imputation. Last observation carried
forward–imputed values were used for missing continuous
variables at week 12. Analysis of covariance, adjusted for the
baseline score, was used to compare change from baseline to
week 12 between the adalimumab and placebo treatment
groups.
To determine the impact of baseline characteristics on
the primary end point, analysis of treatment effect by various
subgroups was performed for the following demographic fea-
tures and baseline disease characteristics: age, sex, weight, SpA
features (evidence of preceding infection, history of IBD, or
anterior uveitis), HLA–B27 status, high-sensitivity C-reactive
protein (hsCRP) level, and concomitant use of DMARDs or
NSAIDs. The Breslow-Day test of homogeneity (odds ratio)
was used to compare treatment effect between the subgroups.
If the differences were significant (P  0.10), a Mantel-
Haenszel test was used to investigate the treatment effect
within each subgroup.
AEs were defined using the Medical Dictionary for
Regulatory Activities (MedDRA) (version 14.0) system organ
classes and preferred terms. AEs were summarized as the
number and percentage of patients experiencing AEs.
RESULTS
Disposition of treatment groups and baseline
characteristics of the patients. There were 165 patients
randomized into the study, of whom 81 were randomized
to receive placebo and 84 to receive adalimumab. Dur-
ing the 12-week double-blind period, 2 patients discon-
tinued the study, both of whom were in the adalimumab
group. One patient discontinued due to the occurrence
of an AE (whole-body dermatitis) and another patient
withdrew consent.
The demographic features and baseline disease
characteristics of the patients were generally comparable
between the treatment groups (Table 1), except that the
mean age was higher in the adalimumab group, and the
percentage of patients with a dactylitis count 1 was
lower in the adalimumab group compared to the placebo
group. There were more women than men in the study
population. A mean delay of 4 years was noted be-
tween symptom onset and SpA diagnosis. At study entry,
the majority of patients were taking a concomitant
NSAID and almost one-half of the patients were taking
a concomitant DMARD. In total, 61% of patients (56%
of the placebo group, 67% of the adalimumab group)
were positive for HLA–B27.
The percentages of patients with other clinical
manifestations or features associated with SpA were
similar in both treatment groups at baseline, except that
there were more patients with a history of preceding
infection characteristic of ReA in the placebo group. At
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baseline, current peripheral arthritis and/or enthesitis
was more prevalent than dactylitis, as evidenced by the
proportion of patients with a TJC 1, SJC 1, total
enthesitis count 1, and dactylitis count 1. Moderate
to high disease activity was noted in both treatment
groups, based on the mean VAS scores for patient’s and
physician’s global assessments of disease activity and on
the BASDAI and ASDAS scores, and more than 40% of
patients had an elevated hsCRP level at baseline. The
baseline SF-36v2 PCS scores indicated impaired physical
Table 1. Demographic features and baseline disease characteristics of the study patients*
Placebo
(n  81)
Adalimumab
(n  84)
Demographics
Female 42 (52) 48 (57)
White 81 (100) 83 (99)
Age, mean  SD years 38.5  12.8 42.5 10.8
Disease characteristics
Symptom duration, mean  SD years 6.6 6.3 7.7 7.9
Duration since SpA diagnosis, mean  SD years 3.0 5.0 4.2 5.6
Prior NSAID use 80 (99) 82 (98)
Concomitant NSAID use at baseline 65 (80) 57 (68)
Prior DMARD use 56 (69) 58 (69)
Concomitant DMARD use at baseline 40 (49) 38 (45)
Methotrexate 23 (28) 22 (26)
Sulfasalazine 25 (31) 19 (23)
Hydroxychloroquine 0 3 (4)
HLA–B27 positive 45 (56) 56 (67)
SpA features
Anterior uveitis, past or present 11 (14) 14 (17)
Inflammatory bowel disease, past or present 3 (4) 5 (6)
Preceding infection† 10 (12) 3 (4)
Family history of SpA 20 (25) 23 (27)
Patient’s global assessment of disease activity (0–100-mm VAS), mean  SD 66  15.9 65  15.2
Patient’s global assessment of pain (0–100-mm VAS), mean  SD 66  15.9 64  14.0
Physician’s global assessment of disease activity (0–100-mm VAS), mean  SD 57 15.0 60  15.5
Tender joints
1 tender joint 80 (99) 83 (99)
Tender joint count (total 78 joints assessed), mean  SD 13.6  16.1 13.0 12.8
Swollen joints
1 swollen joint 76 (94) 78 (93)
Swollen joint count (total 76 joints assessed), mean  SD 7.3  8.0 6.1 5.6
Predominantly lower limb involvement of arthritis‡ 45 (56) 43 (51)
Dactylitis
1 dactylitis site 24 (30) 13 (16)
Dactylitis count, mean  SD 0.7  1.3 0.4 0.9
Enthesitis
1 enthesitis site 73 (90) 70 (83)
Total enthesitis count (total 29 sites assessed), mean  SD§ 7.3  6.7 6.7 7.0
Leeds Enthesitis Index (scale 0–6), mean  SD 1.4 1.6 1.5 1.7
SPARCC Enthesitis Index (scale 0–16), mean  SD 4.1 3.8 3.8 4.0
MASES (scale 0–13), mean  SD 3.6  3.4 3.1 3.6
BASDAI (scale 0–10), mean  SD 5.6 1.6 5.7 1.7
ASDAS, mean  SD 3.1  0.8¶ 2.9 0.8
Elevated hsCRP level 37 (46) 35 (42)
SF-36v2 PCS score (scale 0–100), mean  SD 34.5 7.6 34.6  7.9
HAQ-S score (scale 0–3), mean  SD 1.00 0.5 0.97  0.5
* Except where indicated otherwise, values are the number (%) of patients. SpA spondyloarthritis; NSAID nonsteroidal antiinflammatory drug;
DMARD  disease-modifying antirheumatic drug; VAS  visual analog scale; BASDAI  Bath Ankylosing Spondylitis Disease Activity Index;
ASDAS  Ankylosing Spondylitis Disease Activity Score; hsCRP  high-sensitivity C-reactive protein; SF-36v2 PCS  Short-Form 36 version 2
Health Survey physical component summary; HAQ-S  Health Assessment Questionnaire modified for the Spondyloarthropathies.
† Acute diarrhea or nongonococcal urethritis or cervicitis 1 month before arthritis.
‡ Defined as having a greater number of joints with active disease (swollen and/or tender joints) in the lower limbs than in the upper limbs.
§ Defined as the sum of all unique, individual locations of entheses included in the Leeds Enthesitis Index, Spondyloarthritis Research Consortium
of Canada (SPARCC) Enthesitis Index, and Maastricht Ankylosing Spondylitis Enthesitis Score (MASES).
¶ Total of 80 patients assessed.
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function and poorer health-related quality of life in this
patient population compared to the general population
in the US (26).
Efficacy. A significantly greater percentage of
patients with peripheral SpA treated with adalimumab
achieved a PSpARC40 response at week 12 compared to
patients treated with placebo (33 [39%] of 84 versus 16
[20%] of 81; P  0.006, nonresponder imputation)
(Figure 1A). A significant difference (P  0.01) was
observed as early as week 2 (Figure 1C). The propor-
tions of patients meeting the PSpARC20, PSpARC50,
and PSpARC70 response levels at week 12 were also
significantly greater in the adalimumab group compared
to the placebo group (Figure 1A). Evaluation of
PSpARC response rates based on nonoverlapping cate-
gories indicated that of those patients who met the
primary end point, the PSpARC40, in the adalimumab
group, the majority were PSpARC50 and PSpARC70
responders (Figure 1B).
Based on analyses of treatment effect by various
subgroups, the only significant subgroup predictor of
response to adalimumab was the baseline hsCRP level
(P  0.076 by Breslow-Day test, nonresponder imputa-
tion). Among patients with an elevated hsCRP level at
baseline, 51% of adalimumab-treated patients compared
to 16% of placebo-treated patients were PSpARC40
responders at week 12 (P  0.002, nonresponder impu-
tation), while among those with a normal hsCRP level at
baseline, 31% of adalimumab-treated patients compared
to 23% of placebo-treated patients achieved a
PSpARC40 response (P  0.394, nonresponder imputa-
tion).
Among patients who achieved a PSpARC40 re-
sponse, fulfillment of the response criteria was primarily
due to improvement in the following components: pa-
tient’s global assessment of disease activity VAS score,
patient’s global assessment of pain VAS score, and the
TJC and SJC. A40% improvement and at least 20-mm
improvement in the VAS score for patient’s global
assessment of disease activity (adalimumab 54% versus
placebo 29%; P 0.001) and patient’s global assessment
of pain (adalimumab 54% versus placebo 31%; P 
0.004), and at least 40% improvement in the TJC and
SJC (adalimumab 57% versus placebo 30%; P  0.001)
were observed more frequently in the adalimumab
group compared to the placebo group. There was no
significant difference between the treatment groups with
regard to improvement in the total enthesitis count
(adalimumab 51% versus placebo 42%; P  0.237) and
the dactylitis count (adalimumab 14% versus placebo
19%; P  0.392).
**
**
***
**
**
*
***
***
Figure 1. Improvement in disease activity as measured by the Peri-
pheral SpondyloArthritis Response Criteria (PSpARC) in patients
treated with adalimumab (dark-shaded bars and squares) compared to
those receiving placebo (light-shaded bars and circles). A and B,
PSpARC response rates measured according to 20% (PSpARC20),
40% (PSpARC40; the primary end point), 50% (PSpARC50), and
70% (PSpARC70) levels of improvement at week 12 (A), and PSpARC
response rates presented as nonoverlapping categories (B) (placebo
n  81, adalimumab n  84). C, PSpARC40 response rates in each
treatment group over time.   P  0.05;   P  0.01;   P 
0.001 versus placebo (nonresponder imputation).
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Mean improvements in some of the individual
components of the PSpARC40 (patient’s global assess-
ments of disease activity and pain, TJC, SJC, and total
enthesitis count) were significantly greater with adali-
mumab treatment compared to placebo (Table 2). The
mean change in the dactylitis count was not significantly
different between the groups. However, only a few
patients had dactylitis at baseline (n  13 in the adali-
mumab group and n  24 in the placebo group; mean
baseline dactylitis count 2.2 in the adalimumab group
and 2.2 in the placebo group).
Other measures of disease activity were also
noted to improve by week 12, such as the mean change
in the physician’s global assessment of disease activity,
BASDAI, and hsCRP level (Table 2). Improvement in
physical function and health-related quality of life, as
measured by the SF-36v2 PCS, was observed to be
significantly greater in patients receiving adalimumab
compared to those receiving placebo (P 0.001), but no
significant difference in the HAQ-S scores at week 12
was observed between the adalimumab and placebo
groups. Among patients who had evidence of enthesitis
at baseline (baseline score 1 for the specific enthesitis
index evaluated), significant improvement was observed
with adalimumab as compared to placebo in the Leeds
and SPARCC scores for enthesitis and the total enthesi-
tis count, but not in the MASES (Figure 2). Similarly,
among patients who had a dactylitis count 1 at base-
line, the mean change in dactylitis count at week 12 was
numerically higher in the adalimumab group (mean
change 1.6) compared to the placebo group (mean
change 1.3; P  0.498).
The proportions of patients considered to have
achieved disease remission (according to the PSpARC
criteria) or inactive disease (according to an ASDAS
score 1.3) at week 12 were significantly greater in the
adalimumab group compared to the placebo group
(Figure 3A). In patients with an SJC 1 or TJC 1 at
baseline, more patients had absence of swollen or tender
joints (i.e., achieving an SJC or TJC equal to 0) by week
12 in the adalimumab group compared to the placebo
group (Figure 3B). Moreover, among the patients with a
dactylitis count 1 at baseline (placebo n  24, adali-
mumab n  13), 85% in the adalimumab group had a
dactylitis count of 0 at week 12 compared to 58% in the
placebo group.
Safety. The overall incidence of any AE in the
≥ ≥ ≥ ≥
***
**
*
Figure 2. Improvement in enthesitis among patients with an enthesi-
tis score of 1 at baseline. The mean change in enthesitis from
baseline to week 12 in patients treated with adalimumab (dark-shaded
bars) compared to those receiving placebo (light-shaded bars) was
determined among patients with a baseline enthesitis score of 1,
using the Leeds Enthesitis Index (placebo n  51, adalimumab n 
52), the Spondyloarthritis Research Consortium of Canada
(SPARCC) Enthesitis Index (placebo n 65, adalimumab n 64), the
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) (pla-
cebo n  65, adalimumab n  58), and the total enthesitis count
(placebo n  73, adalimumab n  70). Last observation carried
forward was used for all mean change values.   P  0.05;   P 
0.01;   P  0.001 versus placebo.
Table 2. Mean change from baseline in efficacy variables at week 12*
Placebo
(n  81)
Adalimumab
(n  84) P
Patient’s global assessment of
disease activity (0–100-mm
VAS)
16.4  24.5 27.5  25.8 0.003
Patient’s global assessment of
pain (0–100-mm VAS)
17.1  24.3 28.9  24.7 0.001
Tender joint count 1.8  8.4 5.9  8.7 0.001
Swollen joint count 3.1  5.6 3.6  4.3 0.045
Total enthesitis count 1.5  4.0 2.8  3.9 0.008
Dactylitis count 0.3  0.9 0.2  1.1 0.808
Physician’s global assessment
of disease activity (0–100-
mm VAS)
18.2  22.9 32.2  22.5 0.001
BASDAI 1.0  2.2 2.1  2.3 0.003
HAQ-S score 0.2  0.5 0.3  0.4 0.051
SF-36v2 PCS score† 2.4  6.7 6.7 7.9 0.001
hsCRP level, mg/liter 2.9  11.0 5.5  18.4 0.021
* Except where indicated otherwise, last observation carried forward–
imputed data are shown. Values are the mean  SD change from
baseline to week 12. VAS  visual analog scale; BASDAI  Bath
Ankylosing Spondylitis Disease Activity Index; HAQ-S  Health
Assessment Questionnaire modified for the Spondyloarthropathies;
hsCRP  high-sensitivity C-reactive protein.
† The Short-Form 36 version 2 Health Survey physical component
summary (SF-36v2 PCS) was completed at baseline and week 12 only
(observed analysis; placebo n  79, adalimumab n  83).
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adalimumab group was similar to that in the placebo
group during the double-blind period (Table 3). The
most common events (MedDRA preferred terms) were
nasopharyngitis (14%), upper respiratory tract infection
(5%), and diarrhea (5%) among patients in the placebo
group, and spondyloarthropathy (representing flare of
SpA) (7%), nasopharyngitis (5%), upper respiratory
tract infection (5%), and headache (5%) in the adali-
mumab group. There were 2 serious AEs. A patient in
the placebo group experienced left-sided thoracic pain
that lasted for only 1 day. A patient in the adalimumab
group took an overdose of acetaminophen.
Two patients had an AE during the double-blind
period that led to discontinuation from the study. One
patient withdrew due to the development of whole-body
dermatitis. The other patient withdrew because of the
development of acarodermatitis (scabies) that had
started during the double-blind period, but the patient
completed week 12 and discontinued during the open-
label period. No serious infections, opportunistic infec-
tions, tuberculosis, malignancies, demyelinating disease,
or deaths were reported through week 12.
DISCUSSION
This study is the first to use the ASAS peripheral
SpA criteria to classify patients with nonpsoriatic peri-
pheral SpA and is the largest randomized controlled
trial of an anti-TNF therapy in this population. Find-
ings in this report contribute to the growing knowledge
and understanding of the SpA group of diseases.
Among patients enrolled in this trial, few had a preced-
ing infection characteristic of ReA. The proportion of
patients with accompanying IBD was also low, although
it was within the same range as that reported in typical
phase III anti-TNF trials in patients with AS (25,26).
This indicates that the majority of patients with nonpso-
riatic peripheral SpA in this trial would have been
categorized as having uSpA if the historical disease
***
**
*
**
Figure 3. Measures of disease remission at week 12. A, Remission
rates in each treatment group (adalimumab [n  84] [dark-shaded
bars] versus placebo [n  81] [light-shaded bars]) at week 12 were
determined according to the Peripheral SpondyloArthritis Re-
sponse Criteria (PSpARC), and rates of inactive disease at week 12
were determined according to the Ankylosing Spondylitis Disease
Activity Score (ASDAS), defined as an ASDAS score of 1.3.
  P  0.01;   P  0.001 versus placebo (nonresponder im-
putation). B, Proportions of patients with a baseline value of 1
achieving a value of 0 at week 12 were determined for the swollen
joint count (SJC) (placebo n  76, adalimumab n  76), tender
joint count (TJC) (placebo n  80, adalimumab n  81), and total
enthesitis count (placebo n  73, adalimumab n  69).   P 
0.05;   P  0.01 versus placebo (observed data).
Table 3. Incidence and types of treatment-emergent AEs during the
12-week double-blind period*
Placebo
(n  81)
Adalimumab
(n  84)
Any AE 44 (54) 46 (55)
Serious AE 1 (1) 1 (1)
AE leading to discontinuation
of study drug
0 2 (2)
Infectious AE 23 (28) 18 (21)
Serious infection 0 0
Parasitic infection other than
opportunistic infection
0 1 (1)
Hepatic-related AE 0 1 (1)
Elevated ALT level–related AE 2 (2) 0
Hematologic AE 1 (1) 1 (1)
Death 0 0
* Evaluation of adverse events (AEs) included all patients who re-
ceived at least 1 dose of study medication during the double-blind
period. Values are the number (%) of patients. ALT  alanine
transaminase.
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classification of SpA had been used. Therefore, this
study has demonstrated the potential benefit of adali-
mumab in a group of SpA patients who were previously
excluded from trials of anti-TNF agents for the treat-
ment of AS or PsA.
The nonpsoriatic peripheral SpA patient popula-
tion enrolled in this trial was younger and had a greater
proportion of women compared to the PsA study pop-
ulation enrolled in clinical trials of anti-TNF therapy
(10–13). The mean age at study entry was 40 years,
with 4 years between symptom onset and diagnosis.
This delay may be due to underdiagnosis of this disease
population. The mean TJC and SJC were also lower (13
and 7, respectively) compared to those in patients with
PsA (TJC range 20–26 and SJC range 12–15) (10,11,13)
and were predominantly in the lower limbs in more than
50% of the patients. However, the baseline values for
patient’s and physician’s global assessments of disease
activity and the HAQ-S in this study indicate that the
levels of disease activity and functional impairment were
comparable between patients with nonpsoriatic peri-
pheral SpA and patients with PsA (10–12). The propor-
tion of patients with enthesitis at baseline and the
enthesitis index scores suggest that in addition to peri-
pheral arthritis, enthesitis may have a substantial contri-
bution to the overall burden of disease in nonpsoriatic
peripheral SpA.
This study demonstrated that 39% of patients in
the adalimumab group achieved the primary end point
of PSpARC40 response compared to 20% of patients in
the placebo group. These results suggest that the novel
composite end point of the PSpARC40, which was
developed specifically for this nonpsoriatic peripheral
SpA population, performs well in discriminating the
efficacy of the active drug from the placebo treatment in
this population while enabling a comprehensive evalua-
tion of disease activity. Other cutoff values for the
PSpARC response (PSpARC20, PSpARC50, and
PSpARC70) were also tested, and similar effect sizes
across all 4 PSpARC response thresholds were observed.
Based on subgroup analyses, the presence of an elevated
hsCRP level at baseline was the only significant predic-
tor of the PSpARC40 response to adalimumab therapy
at week 12.
Consistent with previously published reports on
the benefits of anti-TNF therapy in enthesitis (27,28),
significant improvement in enthesitis was demonstrated
following treatment with adalimumab, as indicated by
the Leeds and SPARCC enthesitis indices but not by the
MASES. The MASES was developed for the AS popu-
lation (19) and assesses sites of entheses in primarily
axial locations, in contrast to the Leeds and SPARCC
indices, and thus may not be as suitable for a peripheral
SpA population (17,18). Baseline enthesitis scores were
low, as were the baseline dactylitis counts. Fewer than
25% of patients had dactylitis at baseline. Thus, no
treatment effect on the dactylitis count was noted at
week 12.
Composite measures that have been used previ-
ously in clinical trials of AS were also noted to discri-
minate between active drug and placebo in the present
study. The mean change in the BASDAI and ASDAS
inactive disease response rates were better in patients
treated with adalimumab compared to those receiving
placebo. This may be largely attributed to the compo-
nents that reflect involvement of the peripheral joints
and entheses. These observations are consistent with the
findings in a study by Paramarta et al, in which the
BASDAI50 score (adalimumab 42% versus placebo 5%)
and ASDAS inactive disease score (adalimumab 42%
versus placebo 0%) showed significant improvements in
those treated with adalimumab compared to those re-
ceiving placebo after 12 weeks of therapy (14). In
addition to the ASDAS category of inactive disease,
clinical remission was measured using the PSpARC
remission criteria, with the results demonstrating that
the frequency of disease remission was higher among
patients treated with adalimumab. Furthermore, in the
adalimumab group, significant improvement in function
and health-related quality of life, as measured using the
SF-36v2 PCS, was also observed.
Adalimumab was well tolerated during the 12-
week double-blind study period in this study popula-
tion. There were only 2 serious AEs, and there were no
serious infections, tuberculosis, malignancies, or deaths.
No new safety signal was observed during the 12-week
double-blind period beyond what is already known about
the safety profile of adalimumab in SpA (AS [25], PsA
[10], and nonradiographic axial SpA [29]) and other
immune-mediated diseases (30).
Limitations of this study include the duration of
the double-blind period, which did not allow for a
longer-term analysis of the efficacy of adalimumab com-
pared to placebo in this patient population. Longer
observation is also needed to better characterize the
safety of adalimumab in patients with nonpsoriatic
peripheral SpA. The primary efficacy end point, the
PSpARC40, has not been validated in other peripheral
SpA cohorts. However, validation of this outcome
measure is ongoing. Other cutoff levels (e.g., the
PSpARC50) might better differentiate between active
drug and placebo. The BASDAI and ASDAS are vali-
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dated for patients with AS, but not for patients with
peripheral SpA; however, most of the components used
to calculate the ASDAS are applicable to a peripheral
SpA population.
Patients with nonpsoriatic peripheral SpA can
benefit from alternative, more effective treatment op-
tions. After 12 weeks, adalimumab significantly amelio-
rated the signs and symptoms of disease and improved
physical function in patients with active nonpsoriatic
peripheral SpA who had experienced an inadequate
response or intolerance to NSAIDs. The safety profile of
adalimumab in this patient population was consistent
with the well-established safety of adalimumab in mul-
tiple immune-mediated diseases. Longer-term data are
needed to confirm and support the current findings of a
favorable benefit–risk profile of adalimumab in patients
with nonpsoriatic peripheral SpA.
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